Uterine Pathology in Hysterectomies Performed for Treatment of Pelvic Organ Prolapse

Foust-Wright CE, Pilliod RA, Weinstein MM, Johnson AM, Batalden RP and Pulliam SJ*

Department Obgyn, Division of Female Pelvic Medicine and Reconstructive Surgery, 55 Fruit Street, Yawkey 5, Boston, MA 02114, USA

***Corresponding author:** Samantha Pulliam, Massachusetts General Hospital, Department Obgyn, Division of Female Pelvic Medicine and Reconstructive Surgery, 55 Fruit Street, Yawkey 5, Boston, MA 02114, USA, Tel: 617-724-9014; Fax: 617-726-4267; E-mail: VSXOOLDP#SDUWQHUV RUJ

Rec date: October 05, 2015; **Acc date:** October 21, 2015; **Pub date:** November 05, 2015

Abstract

Objective: To determine the rate of uterine pathology in hysterectomies performed during surgery for treatment of uterovaginal prolapse.

Methods: In this retrospective cohort study, we evaluated all patients undergoing hysterectomy during treatment of uterovaginal prolapse at a single academic institution from 2008 to 2013. Demographics, risk factors for uterine malignancy, operative data, and pathology reports were reviewed. Patients with history of concerning uterine pathology were excluded.

Results: 339 subjects were included; none were excluded. Mean age of patients undergoing hysterectomy was 63.2 years with 85.5% post-menopausal. Mean BMI was 27 kg/m^2 and mean uterine weight was 71 grams. Abnormal pathology was identified in 0.8% (3/339) subjects: complex atypical hyperplasia (1), grade 1 endometrial adenocarcinoma (1), and low-grade B-cell lymphoma (1). 49% of specimens contained fibroids and no sarcomas were identified. Total hysterectomy was performed in 88%. 12% (40/339) underwent supracervical hysterectomy with morcellation. One specimen with abnormal pathology (complex atypical hyperplasia) was morcellated. Patients undergoing procedures requiring morcellation were younger (57.3 vs. 63.3, p=.001, 95%CI 2.52, 9.52) and less likely to be postmenopausal (69% vs. 88%, p=.021, 95%CI .067, .300). Risk factors for uterine malignancy were not different between groups.

Conclusions: We found a low rate of incidental uterine pathology in hysterectomy specimens from prolapse surgery. Half of uterine specimens had leiomyomas. Specimens with fibroids had a higher mean weight than leiomyoma-free specimens. Risk factors for cancers among patients undergoing morcellation versus intact removal were not different. Further study is needed to clarify the role of morcellation in this low-risk population.

Keywords: 8WHULQH SDWKRORJ\ 0RUFHOODWLRQ

,QWURGXFWLRQ

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

0DWHULDOV DQG 0HWKRGV

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

SUHPDOLJQDQW SDWKRORJLFW JURXS VXEMHFWV JUDGH HQGRPHWULDO DGHQRFDUFLQRPD DQG ORZ JUDGH % FHOO O\PSKRPD 2QH SUHPDOLJQDQW VSHFLPHQ [DW\SLFDO K\SHUSODVLD ZDV PRUHOODWHG 7DEOH SDWKRORJLFDO SURFHGXUH LQFOXGLQJ SRZHU PRUHOODWLRQ ZHUH &, DQG OHVV OLNHO\ WR EH S &, 5LVN IDFWRUV LQFOXGLQJ %0, SUHJQDQF\ PHOLWXV EUHDVW FDQFHU RU VHOI ZHUH VLJQLILFDQWO\ DVVRFLDWHG VSHFLPHQ ZDV PRUHOODWHG ZLWK FRPSOH[KDYH DQ\ ULVN IDFWRUV RI XWHULQH DGGLWLRQDO VXUJHULHV 6KH KDV QR HYLGHQFH RI VXUYHLOODQFH

'HQLWWRQV %RG\ 0DVV ,QGH[+[+LVWRU\ (VWURJHQ 5HFHSWRU 0RGXODWRU HUDS+\VW +\VWHUHFWRP\ 79+ 7RWDO /6&+ /DSDURVFRSLF 6XSUDFHUYLFDO 5RERWLFDOO\ DVVLVWHG 6XSUDFHUYLFDO DSDURVFRSLF DVVLVWHG 9DJLQDO +\VWHUHFWRP\

	All (n=339)	Morcellated uteri (n=40)	Intact uteri (n=299)	p-value
Uterine wt (gms)	71.06 (3.97)# [63.25-78.87]**	65.97 (48.9)# [49.16-82.77]**	71.68 (73.86)# [63.13-80.21]**	0.656
Fibroids present (%)		55 (22/40)	48 (144/299)	0.417
Adenomyosis (%)		23 (9.2/40)	22 (66/299)	0.891
Endometrium (n)—				0.411
Normal / Benign	336	39	297	
Complex hyperplasia	1	1	0	
Endometrial cancer	1	0	1	
Other malignancy	1	0	1	
#Standard deviation *Range **95% Confidence interval				

7DEOH SDWKRORJ\ VSHFLPHQ FKDUDFWHULVWLFV LQ ZRPHQ XQGHUJRLQJ K\VWHUHFWRP\ IRU SURODSVH

	All (n=339)	Fibroids present (n=166)	Fibroids absent (n=173)	p-value
Uterine wt (gms)		55.05 (34.71)# [49.74-60.38]**	87.43 (93.49)# [72.69-102.17]**	0.0001
#Standard deviation *Range **95% Confidence interval				

7DEOH HWHULQH ZHLJKW LQ SDWKRORJ\ VSHFLPHQV DFFRUGLQJ WR SUHVHQFH RI OHLRP\RPD

5HIHUHQFHV

+HQGUL[6/ &ODUN $ 1\JDDUG , $UDJDNL V DQG %UDGVKDZ 3 3HUVRQDOLW\ DQG ULVN DVVHVVPHQW RI 3HUVRQDOLW\ 3HUVRQDOLW\ DQG ULVN DVVHVVPHQW RI 3HUVRQDOLW\ DQG JUDYLGLW\ $P - 2EVWHW *\QHFRO

:X -0 0DWWKHZV &$ &RQRYHU 00 3DWH 9 -RQVVRQ)XQN 0 /LIHWLPH ULVN RI VWUHVV XULQDU\ LQFRQWLQHQFH RU SHOYLF RUJDQ SURODSVH VXUJHU\ 2EVWHW *\QHFRO

0DKHU &)HLQHU % %DHVVOHU . 6FKPLG & 6XUJLFDO PDQDJHPHQW RI SHOYLF RUJDQ SURODSVH LQ ZRPHQ &RFKUDQH 'DWDEDVH 6\VW 5HY &'

2VPXQG%%Q&ODUN $ *ROGVPLWK & $GDPV . 'HQPDQ 0$ HW DO 0HVK HURVLRQ LQ URERWLF VDFURFROSRSH[\ )HPDOH 3HOYLF 0HG 5HFRQVWU 6XUJ